Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | LGALS9 | O00182 | 3/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.46 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.46 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 6/20 | 0.44 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.44 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.44 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21391505 | 1.00 | CA12 (0.46) | CA12CA1CA2CA9CA14 | |
| SCHEMBL22906136 | 1.00 | CA12 (0.46) | CA12CA1CA2CA9CA14 | |
| SCHEMBL21391507 | 0.88 | FGF1 (0.51) | CA12CA1CA2CA9CA14 | |
| SCHEMBL21391436 | 0.88 | FGF1 (0.51) | CA12CA1CA2CA9CA14 | |
| SCHEMBL21391537 | 0.88 | FGF1 (0.51) | CA12CA1CA2CA9CA14 | |
| SCHEMBL21391440 | 0.86 | CA12 (0.44) | CA12CA1CA2CA9CA14 | |
| SCHEMBL10102995 | 0.80 | TYR (0.63) | CA12CA1CA2CA9TYR | |
| SCHEMBL10102994 | 0.80 | TYR (0.63) | CA12CA1CA2CA9TYR | |
| SCHEMBL10103032 | 0.80 | TYR (0.63) | CA12CA1CA2CA9TYR | |
| SCHEMBL10103034 | 0.80 | TYR (0.63) | CA12CA1CA2CA9TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210017211-A1 | OLIGOSACCHARIDE C-GLYCOSIDE DERIVATIVES | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2021-01-21 | — | — | US | disclosed |
| WO-2019182087-A1 | OLIGOSACCHARIDE C-GLYCOSIDE DERIVATIVES | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017211-A1 | OLIGOSACCHARIDE C-GLYCOSIDE DERIVATIVES | OSTC, FUT6, FUT5 | CA12 155/4885CA1 1659/4885CA2 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.